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Intracranial inoculation of susceptible SJL mice with Theiler’s murine encephalomyelitis virus (TMEV) results in biphasic
disease consisting of early acute disease, followed by late chronic demyelinating disease, associated with mononuclear
infiltrates and demyelinating lesions. In contrast, resistant C57BL/6 (B6) mice develop only early acute disease. We employed
cytokine-specific RT-PCR to determine the expression of cytokine transcripts in the CNS of TMEV-infected SJL and B6 mice.
During early acute disease, we have found a strong proinflammatory (Th1) cytokine response in the CNS of both TMEV-
infected SJL and B6 mice, demonstrated by the expression of transcripts for IFN-g, IL-1, IL-6, IL-12p40, and TNF-a. At 8 days
postinfection (p.i.), TGF-b1 and TNF-a transcripts were present at significantly higher levels (P , 0.01) in the CNS of SJL
susceptible mice in comparison to those found in the CNS of B6 mice. Immunohistochemical staining revealed that TGF-b
protein was expressed in leptomeningeal mononuclear inflammatory cell infiltrates in the brain of SJL mice but not in B6 mice,
at 8 days p.i. TGF-b may be responsible for the failure of SJL mice to develop an effective anti-TMEV CTL response. During
late chronic demyelinating disease, high levels of proinflammatory Th1 cytokines were found in the CNS of SJL mice, but not
B6 mice. Significantly higher levels (P , 0.01) of anti-inflammatory cytokine transcripts (IL-4, IL-5, and IL-10 (Th2 cytokines)
and TGF-b) were found in the spinal cord of TMEV-infected SJL mice with chronic demyelinating disease than in the spinal
cord of B6 mice during the same time period (39 or 60 days p.i.). These anti-inflammatory cytokines may contribute to the
downregulation of the proinflammatory response in SJL mice. High levels of IL-2 transcripts and protein appeared transiently
in the spinal cord of TMEV-infected SJL mice before the onset of demyelinating disease and coincided with an influx of new
T cells into the CNS and/or expansion of remaining T cells that have not been eliminated after viral clearance. © 2000 Academic
Press
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1INTRODUCTION
Theiler’s murine encephalomyelitis virus (TMEV) is a
single-stranded RNA virus that belongs to the Picorna-
viridae (reviewed by Dal Canto et al., 1996; Monteyne et
al., 1997; Oleszak et al., 1995; Tsunoda and Fujinami,
1996). Intracranial (ic) infection of susceptible strains of
mice, such as SJL mice, with the DA strain of TMEV
induces biphasic disease, namely, early acute disease
resembling polioencephalomyelitis, followed by late
chronic demyelinating disease. In contrast, resistant
strains of mice, such as C57BL/6 (B6) mice, develop only
early acute disease and clear the virus in about 3 weeks.
Although the viral titer is greatly reduced after early acute
disease, susceptible strains of mice fail to clear the virus,
which persists in microglia/macrophages, astrocytes,
and oligodendrocytes. Both early acute demyelinating
disease and late demyelinating disease are associated
with extensive infiltration of the CNS primarily by CD41
1 To whom correspondence and reprint requests should be ad-
ressed at Fels Institute for Cancer Research and Molecular Biology,
emple University School of Medicine, 3307 North Broad Street, Phil-
delphia, PA 19140. Fax: (215) 829-1320.
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346and CD81 T cells, monocytes/macrophages, a few B
ells, and plasma cells (reviewed by Dal Canto et al.,
996; Monteyne et al., 1997; Oleszak et al., 1995; Tsunoda
and Fujinami, 1996).
Studies investigating TMEV infection in mice with ge-
netically deleted CD4 or CD8 (Fiette et al., 1996; Murray
et al., 1998; Njenga et al., 1996) as well as other studies
(Miller and Rodriguez, 1995; Rivera-Quinones et al., 1998)
suggest that both CD41 and CD81 T cells play an im-
portant role in clearance of the virus and the develop-
ment of demyelinating disease, although their antigenic
specificity (host or viral) is unknown.
Demyelinating disease appears to be associated with
viral persistence in the CNS (Murray et al., 1998; Njenga
et al., 1996). It has been suggested that the ability of
TMEV to establish persistent infection in the CNS is
associated with upregulation of MHC class I on cerebro-
vascular endothelial cells, which potentially could
present antigen to T cells. The inability of susceptible SJL
mice to clear the virus leads to demyelinating disease. In
contrast, the ability of B6 mice to completely clear the
virus results in complete recovery. Resistant B6 mice are
able to generate strong TMEV-specific cytotoxic T lym-
phocytes (CTL) as early as 3 days postinfection (p.i.),
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347CYTOKINES IN TMEV INFECTIONwhile weak virus-specific CTL appear much later in the
CNS of SJL mice and they remain at very low levels
throughout the infection (Dethlefs et al., 1997; Lin et al.,
995; Lindsley et al., 1991). The reason that SJL mice, in
ontrast to B6 mice, are not able to generate a prompt
nd strong CTL response is not known. Clearance of the
irus from the CNS requires migration of cells of the
mmune system to the site of infection and antigen-
riven differentiation of T cells to antiviral CD4 and CD8
ells (reviewed by Perry et al., 1995; Martiney et al.,
998). The inflammatory response is heavily dependent
n cytokine and chemokine production by cells of both
he immune system and the CNS. Cytokines are essen-
ial in enhancing and propagating immune responses to
iral infections and to suppress these responses after
iral clearance. Previous studies (Sato et al., 1997; Be-
olka et al., 1998; Theil et al., 2000) examined cytokine
ranscripts in the brain of TMEV-infected mice, without
dentifying particular cytokines or cytokine patterns as-
ociated with susceptibility or resistance to TMEV-in-
uced demyelinating disease or with the inability of the
JL mice to clear the virus. Sato et al. (1997) reported the
resence of predominantly Th1 cytokine transcripts dur-
ng early acute and late chronic demyelinating disease,
ith variable expression of Th2 cytokine transcripts. The
uthors concluded that particular cytokines or cytokine
atterns were not associated in this study with suscep-
ibility or resistance to TMEV-induced demyelinating dis-
ase or with particular stages of TMEV infection in gen-
ral, perhaps because only four time points were exam-
ned during the course of the disease. Begolka et al.
1998) studied the expression of IFN-g, TNF-a, IL-10, and
IL-4 transcripts in the spinal cord of TMEV-infected
(BeAn strain) SJL mice. The BeAn strain causes consid-
erably different disease than the DA strain. In contrast to
the DA strain, the BeAn-induced encephalitic stage is
more attenuated. The onset of clinical signs associated
with demyelinating disease appear as early as 30 days
p.i. Expression of IFN-g and TNF-a transcripts correlated
with the peak of clinical severity. In contrast, IL-10 and
IL-4 transcripts were continuously expressed throughout
the chronic-progressive course of the disease (Begolka
et al., 1998).
We report here for the first time the presence of certain
significant differences in the expression of cytokine tran-
scripts in the CNS of TMEV-infected susceptible (SJL) vs
resistant (B6) mice. These cytokines may play an impor-
tant role in the pathogenesis of the disease and in
generation of persistent infection.
RESULTS
The course of ic infection of SJL mice with TMEV was
evaluated by histopathological examination of the CNS
at 8, 14, 21, 25, 28, 33, 39, and 60 days p.i. TMEV infection
of SJL susceptible mice resulted in a typical biphasic
(
mdisease of the CNS consisting of early acute disease
(polioencephalomyelitis), followed by late chronic demy-
elinating disease (data not shown). In contrast, B6 mice,
which are resistant to TMEV-induced demyelinating dis-
ease, developed only early acute disease, cleared the
virus, and did not develop late chronic demyelinating
disease (data not shown). These results are typical of
those reported previously (reviewed by Dal Canto et al.,
1996; Monteyne et al., 1997; Oleszak et al., 1995; Tsunoda
and Fujinami, 1996).
We have examined the expression of transcripts of
proinflammatory (IFN-g, IL-1, IL-2, IL-6, IL-12, and TNF-a)
nd anti-inflammatory cytokines (TGF-b1, IL-4, IL-5, and
IL-10) in the brain and spinal cord of TMEV-infected SJL
or B6 mice by RT-PCR, followed by Southern blotting with
cytokine-specific probes and scanning densitometry, as
described under Materials and Methods. Cytokine tran-
scripts in the brain or spinal cord of control uninfected
SJL mice were either absent/negligible or present at very
low levels (IFN-g, IL-1, IL-2, IL-12, TGF-b1, IL-4, IL-5, and
IL-10), with the exception of IL-6 and TNF-a, which were
present at higher levels. These results are shown in Figs.
1 and 2 (day 0) and are in agreement with the reports of
others (Donnelly et al., 1997; Mokhtarian et al., 1996;
esselingh et al., 1994).
Transcripts of various cytokines were examined in the
rain and spinal cord of mock-infected SJL (n 5 5) and
6 (n 5 5) mice, at 0 and 8 days p.i., and were, in
general, absent or present at very low levels. IL-2, IL-4,
and IFN-g were either absent or present at negligible
evels in the brain or spinal cord of mock-infected SJL
nd B6 mice at 0 and 8 days p.i.
Transcripts for TGF-b, TNF-a, IL-1, IL-6, IL-10, and IL-12
ere expressed at low or negligible levels in the CNS of
ock-infected SJL and B6 mice, as follows: (a) TGF-b
transcripts were absent from the brain and the spinal
cord of SJL and B6 mice at 0 days p.i.; at 8 days p.i., brain:
SJL mice 0.027 6 0.008 vs B6 mice 0.0 6 0.0 (mean 6
SEM; percentage of b-actin; see Materials and Methods)
(P 5 0.0075; Wilcoxon two-sample test). Additionally,
rains from mock-infected SJL or B6 mice at 8 days p.i.
id not express any TGF-b protein (see below). At 8 days
.i., spinal cord: SJL mice 0.026 6 0.005 vs B6 mice
.004 6 0.003 (P 5 0.02; Wilcoxon two-sample test). (b)
NF-a: 0 days p.i., brain: SJL mice 0.091 6 0.012 vs B6
mice 0.009 6 0.005 (P 5 0.003); spinal cord: SJL mice
0.138 6 0.023 vs B6 mice 0.044 6 0.007 (P 5 0.013); 8
ays p.i., brain: SJL mice 0.206 6 0.018 vs B6 mice
.125 6 0.02 (P 5 0.018); spinal cord: SJL mice 0.138 6
.011 vs B6 mice 0.179 6 0.061 (P 5 0.198). (c) IL-1: 0
ays p.i., brain: SJL mice 0.130 6 0.008 vs B6 mice
.054 6 0.015 (P 5 0.005); spinal cord: SJL mice 0.132 6
.005 vs B6 mice 0.094 6 0.009 (P 5 0.055); 8 days p.i.,
rain: SJL mice 0.168 6 0.008 vs B6 mice 0.147 6 0.005P 5 0.06); spinal cord: SJL mice 0.170 6 0.003 vs B6
ice 0.157 6 0.008 (P 5 0.193). (d) IL-6: 0 days p.i.,
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348 CHANG ET AL.brain: SJL mice 0.112 6 0.038 vs B6 mice 0.02 6 0.008
(P 5 0.089); spinal cord: SJL mice 0.045 6 0.036 vs B6
ice 0.019 6 0.009 (P 5 0.617); 8 days p.i., brain: SJL
ice 0.230 6 0.009 vs B6 mice 0.121 6 0.025 (P 5
0.009); spinal cord: SJL mice 0.222 6 0.008 vs B6 mice
0.145 6 0.022 (P 5 0.021). (e) IL-10: 0 days p.i., brain:
JL mice 0.131 6 0.008 vs B6 mice 0.022 6 0.011 (P 5
.000); spinal cord: SJL mice 0.159 6 0.007 vs B6 mice
.086 6 0.009 (P 5 0.013); 8 days p.i., brain: SJL mice
.123 6 0.006 vs B6 mice 0.127 6 0.012 (P 5 0.736);
pinal cord: SJL mice 0.126 6 0.011 vs B6 mice 0.157 6
FIG. 1. Proinflammatory cytokine transcript levels of TMEV-infected
isease. Cytokine transcript levels were quantitated as described un
ranscript levels between the SJL and the B6 mice are marked by an
escribed under Materials and Methods..014 (P 5 0.129). Mock-infected SJL mice at 62 days
.i. expressed in the spinal cord negligible/very low lev-
a
sls of IFN-g, IL-1, IL-2, TNF-a, and IL-4 (data not shown).
imilar results for cytokine transcripts in the CNS of
ormal SJL and B6 mice have been reported by Mokhtar-
an et al. (1996).
roinflammatory (Th1) cytokine transcripts in the
rain and spinal cord of TMEV-infected SJL
nd B6 mice
IFN-g. The levels of IFN-g transcripts were high in the
rain of TMEV-infected SJL and B6 mice during early
d B6 mice during early acute disease and late chronic demyelinating
aterials and Methods. Statistically significant differences in cytokine
in the figure, are described under Results, and were determined asSJL an
der Mcute disease (Fig. 1A). IFN-g transcript levels were
ignificantly higher in the brain of SJL mice than in those
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349CYTOKINES IN TMEV INFECTIONof B6 mice, at 14 days p.i. (P , 0.027, Kruskal–Wallis
test; P , 0.037, Wilcoxon two-sample test) and at 21
days p.i. (P , 0.014, Kruskal–Wallis test; P , 0.02,
Wilcoxon two-sample test). Subsequently, IFN-g tran-
cripts in the brain of SJL and B6 mice were gradually
ecreased to lower levels starting at 25 days p.i. and
emained at these levels during late chronic demyelinat-
ng disease, although they were significantly higher in
JL mice than in B6 mice, at 39 days p.i. (P , 0.016,
ruskal–Wallis test; P , 0.021, Wilcoxon two-sample
est) and at 60 days p.i. (P , 0.013, Kruskal–Wallis test;
, 0.019, Wilcoxon two-sample test). During the first
0 days p.i. there were no differences in the levels of
FIG. 1FN-g transcripts in the spinal cord of SJL and B6 mice
(Fig. 1B). A second peak of IFN-g was evident at 25 days.i. in the spinal cord of SJL mice only. IFN-g transcripts
remained at high levels in the spinal cord of SJL mice
during late chronic demyelinating disease and were sig-
nificantly higher than those of B6 mice at 60 days p.i.
(P , 0.010, Kruskal–Wallis test; P , 0.015; Wilcoxon
two-sample test). In contrast to TMEV-infected SJL mice,
IFN-g transcripts were gradually decreased in the spinal
ord of B6 mice and fell below detectable levels at 60
ays p.i.
IL-1. There were certain moderate but statistically sig-
ificant differences in IL-1 transcript levels in the brain of
MEV-infected SJL mice vs those of B6 mice, at 8 days
.i. (P , 0.028, Kruskal–Wallis test; P , 0.036, Wil-
inuedcoxon two-sample test), at 14 days p.i. (P , 0.014,
Kruskal–Wallis test; P , 0.02, Wilcoxon two-sample
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350 CHANG ET AL.test), at 21 days p.i. (P , 0.05, Kruskal–Wallis test; P ,
.066, Wilcoxon two-sample test), at 39 days p.i. (P ,
0.028, Kruskal–Wallis test; P , 0.036, Wilcoxon two-
sample test), and at 60 days p.i. (P , 0.014, Kruskal–
Wallis test; P , 0.02, Wilcoxon two-sample test) (Fig.
C). IL-1 transcript levels were comparable in the spinal
ord of TMEV-infected SJL and B6 mice, up to 39 days p.i.
Fig. 1D). IL-1 transcript levels were significantly higher
n the brain (P , 0.014, Kruskal–Wallis test; P , 0.02,
ilcoxon) and spinal cord (P , 0.014, Kruskal–Wallis
est; P , 0.02, Wilcoxon two-sample test) of SJL mice
han of those of B6 mice, at 60 days p.i.
IL-2 transcripts. IL-2 transcript levels were low and not
ignificantly different in the brain of TMEV-infected SJL
nd B6 mice up to 60 days p.i. (Fig. 1E) and in the spinal
ord of SJL and B6 mice up to 20 days p.i. However, a
ubstantial increase in IL-2 transcript levels was ob-
erved in the spinal cord of SJL mice only (Fig. 1F),
efore the onset of the demyelinating phase of the dis-
ase, at 25 to 39 days p.i. (at 28 days p.i., P , 0.047,
ruskal–Wallis test; P , 0.060, Wilcoxon two-sample
est; at 39 days p.i., P , 0.046, Kruskal–Wallis; P ,
.061, Wilcoxon two-sample test). This increase in IL-2
ranscript levels in the spinal cord was observed in five
f five TMEV-infected SJL mice.
IL-2 protein. Expression of IL-2 protein was deter-
ined by intracellular staining for IL-21 T cells, using a
double-color immunofluorescence method, as described
under Materials and Methods. A substantial increase in
IL-2 transcript levels was observed in the spinal cord of
SJL mice only (Fig. 1F), before the onset of the demyeli-
nating phase of the disease, at 25 to 39 days p.i. This
increase in the transcript levels was associated with a
substantial increase in the proportions of T cells that
expressed IL-2 protein. A substantial increase in CD31
IL-21 cells and of the percentage of CD31 cells produc-
ing IL-2 was observed in the spinal cord of TMEV-in-
fected SJL mice at 39 days p.i. vs those observed in the
brain of these mice at 8 days p.i. (Table 1). In a separate
experiment we determined that 5.6% of the CD41 cells
produced IL-2. In the same experiment 5.6% of the CD81
cells produced IL-2 (Table 1). The percentage of CD31
cells producing IL-2 cells in the brain of TMEV-infected
B6 mice at 8 days p.i. was substantially higher than that
found in the brain of TMEV-infected SJL mice (Table 1).
These results are in agreement with the statistically
significantly higher levels of TGF-b transcripts found in
he brain of SJL mice than in those found in the brain of
6 mice (see below). It has been demonstrated that after
arly acute disease (between 20 and 25 days p.i.) the
umber of T cells in the CNS of SJL mice is hardly
etectable before rising again (Lindsley and Rodriguez,
989). Our results confirm that the increased level of IL-2
both transcript and protein) is observed in SJL mice just
efore the onset of demyelinating disease and this event
ay coincide with an influx of new T cells into the CNS
W
end/or expansion of remaining T cells that have not been
liminated after viral clearance.
IL-6. IL-6 transcripts were expressed at high levels in
he brain (Fig. 1G) and spinal cord (Fig. 1H) of TMEV-
nfected SJL and B6 mice. The levels of IL-6 transcripts
ere not significantly different in SJL and B6 mice, with
he following exceptions: (a) in the brain at 14 days p.i.
P , 0.05, Kruskal–Wallis test; P , 0.066, Wilcoxon
wo-sample test); at 28 days p.i. (P , 0.047, Kruskal–
allis test; P , 0.06, Wilcoxon two-sample test); and at
9 days p.i. (P , 0.007, Kruskal–Wallis test; P , 0.009,
ilcoxon two-sample test); (b) in the spinal cord at 39
ays p.i. (P , 0.013, Kruskal–Wallis test; P , 0.019,
TABLE 1
Percentage IL-2-Positive T Cells Determined by Intracellular Stain-
ng in the CNS of TMEV-Infected SJL and B6 Mice during Early Acute
isease and Late Chronic Demyelinating Disease
A. TMEV-infected SJL mice
Days p.i.
CD31 IL-22
(%)a
CD31 IL-21
(%)a
% of CD31 cells
producing IL-2
8b 38.0 0.3 0.8
39c 48.4 2.1 4.2
40c 72.2 0.4 0.5
Control
MiCK-1d 29.0 11.6 40.0
B. TMEV-infected SJL mice
Days p.i.
CD41 IL-22
(%)
CD41 IL-21
(%)
% of CD41 cells
producing IL-2
30c 33.8 2.0 5.6
ontrol
MiCK-1d 19.6 8.4 43.0
Days p.i.
CD81 IL-22
(%)
CD81 IL-21
(%)
% of CD81 cells
producing IL-2
30c 13.4 0.8 5.6
ontrol
MiCK-1d 6.0 1.5 25.0
C. TMEV-infected B6 mice
Days p.i.
CD31 IL-22
(%)
CD31 IL-21
(%)
% of CD31 cells
producing IL-2
8b, e 12.5 1.8 12.6
a CD31 IL-22, CD31 IL-21, CD41 IL-22, CD41 IL-21, CD81 IL-22,
CD81 IL-21 cells were determined by double staining as described
nder Materials and Methods.
b Brain.
c Spinal cord.
d Positive control: MiCK-1 cells were stained as described under
Materials and Methods. Representative results.
e Positive control: MiCK-1 cells were 6.9% IL-21.ilcoxon two-sample test). The most substantial differ-
nces in the levels of IL-6 transcripts in SJL vs B6 mice
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351CYTOKINES IN TMEV INFECTIONwere observed at 39 days p.i., corresponding to the
demyelinating stage of the disease.
IL-12 p40. High levels of IL-12 p40 transcripts were
observed in the brain of SJL and B6 mice during early
acute disease (Fig. 1I). Statistically significant differ-
ences in IL-12 p40 transcript levels between SJL and B6
mice were found in the brain at day 14 p.i. (P , 0.014,
ruskal–Wallis test; P , 0.02; Wilcoxon two-sample
test), at day 28 p.i. (P , 0.009, Kruskal–Wallis test; P ,
.012, Wilcoxon two-sample test), and at day 39 p.i. (P ,
.008, Kruskal–Wallis test; P , 0.011, Wilcoxon two-
ample test). In the spinal cord (Fig. 1J), low levels of
L-12 p40 transcripts were found in TMEV-infected SJL
nd B6 mice up to 60 days p.i., when a substantial
ncrease in IL-12 p40 transcript levels was observed in
he spinal cord of TMEV-infected SJL, but not B6, mice (at
9 days p.i., P , 0.014, Kruskal–Wallis test; P , 0.02,
ilcoxon two-sample test). Similar transient increases in
FN-g and IL-2 transcript levels (Figs. 1B and 1F, respec-
tively) were observed at the onset of demyelinating dis-
ease.
TNF-a. Significant differences were also observed in
TNF-a transcript levels between SJL and B6 mice. During
early acute disease, at 8 days p.i., significantly higher
levels (about threefold) of TNF-a transcripts were ob-
served in the brain (P , 0.009, Kruskal–Wallis test; P ,
.012, Wilcoxon two-sample) (Fig. 1K) and spinal cord
P , 0.014, Kruskal–Wallis test; P , 0.02, Wilcoxon
wo-sample test) (Fig. 1L) of TMEV-infected SJL mice
han in those of B6 mice. Significantly higher levels of
NF-a transcripts were also found in the brain of SJL
ice at 14 days p.i. (P , 0.05, Kruskal–Wallis test; P ,
.066, Wilcoxon two-sample test). In contrast, at 21 days
.i. higher levels of TNF-a transcripts were found in the
brain of B6 mice (P , 0.05, Kruskal–Wallis test; P ,
0.066, Wilcoxon two-sample test).
Significantly higher levels of TNF-a transcripts were
bserved in the brain (P , 0.009, Kruskal–Wallis test;
P , 0.012, Wilcoxon two-sample test) (Fig. 1K) and
spinal cord (P , 0.009, Kruskal–Wallis test; P , 0.012,
Wilcoxon two-sample test) (Fig. 1L) of SJL mice at 28
days p.i. At 39 days p.i. TNF-a transcript levels remain
igher in the brain (P , 0.009, Kruskal–Wallis test; P ,
.012, Wilcoxon two-sample test) and the spinal cord
P , 0.014, Kruskal–Wallis test; P , 0.02, Wilcoxon
wo-sample test) of TMEV-infected SJL than in those of
6 mice. Differences in TNF-a transcript levels in the
pinal cord of TMEV-infected SJL vs B6 mice at 60 days
.i. were not statistically significant.
A bimodal distribution of TNF-a transcripts was ob-
served in the brain of TMEV-infected SJL mice with one
peak during early acute disease (8 days p.i.) and a
second peak at the onset of the demyelinating phase of
the disease (25–33 days p.i.) (Fig. 1K). In addition to
TNF-a transcripts, a similar bimodal distribution was
observed with IL-1 (Fig. 1C), IL-6 (Fig. 1G), and IL-12 p40(Fig. 1I) transcripts in the brain of TMEV-infected SJL
mice. A bimodal distribution was also observed with
IFN-g (Fig. 1B), IL-6 (Fig. 1H), and TNF-a (Fig. 1L) tran-
scripts in the spinal cord of TMEV-infected SJL mice. Two
peaks can be clearly distinguished, one during early
acute disease and one at the onset of the demyelinating
disease. These bimodal distributions were not seen in
TMEV-infected B6 mice, which exhibited in the brain only
a broad peak of IL-1, IL-2, IL-12 p40, and TNF-a tran-
scripts during the first 30 days p.i. These differences in
the distributions of cytokine transcripts resulted in mod-
erately, but statistically significantly higher levels of IL-1,
IL-12 p40, and TNF-a transcripts in the brain of B6 mice
than in that of SJL mice at days 21 or 25 p.i. (Fig. 1).
Anti-inflammatory cytokine transcripts in the brain
and spinal cord of TMEV-infected SJL and B6 mice
TGF-b1 transcripts. Statistically significant differences
were observed in TGF-b1 transcript levels between SJL
and B6 mice. During early acute disease (8 days p.i.)
significantly higher levels of TGF-b1 transcripts were
ound in the brain (P , 0.009, Kruskal–Wallis test; P ,
0.012; Wilcoxon two-sample test) and the spinal cord
(P , 0.014, Kruskal–Wallis test; P , 0.02; Wilcoxon
wo-sample test) of TMEV-infected SJL mice (Fig. 2A).
hese levels in SJL mice were approximately nine-fold
igher than those observed in TMEV-infected B6 mice
Fig. 2A). Additionally, significantly higher TGF-b1 tran-
cript levels were found during late chronic demyelinat-
ng disease in the brain of SJL mice than that of B6 mice
t 39 days p.i. (P , 0.009, Kruskal–Wallis test; P ,
.012, Wilcoxon two-sample test) and at 60 days p.i.
P , 0.014, Kruskal–Wallis test; P , 0.02; Wilcoxon
wo-sample test) and in the spinal cord of SJL than that of
6 mice at 60 days p.i. (P , 0.014, Kruskal–Wallis test;
, 0.02, Wilcoxon two-sample test).
TGF-b protein. Frozen sections of brain tissue from
TMEV-infected SJL (sensitive) and B6 (resistant) mice, at
8 days p.i., were stained by immunohistochemistry using
a pan-specific rabbit anti-TGF-b polyclonal antibody.
Strong immunostaining was observed in the brain of
TMEV-infected SJL mice at 8 days p.i. (Fig. 3). TGF-b
protein was evident in mononuclear cell infiltrates pri-
marily found in the leptomeninges of the medial temporal
lobe of SJL mice, but not in the parenchyma (Fig. 3A).
Immunostaining of adjacent cryostat brain sections from
TMEV-infected susceptible SJL mice, at 8 days p.i., with
control antibody was negative (Fig. 3B). Immunostaining
with this anti-TGF-b antibody of cryostat brain sections
from mock-infected SJL mice, at 8 days p.i., was negative
(data not shown). Immunostaining of cryostat brain sec-
tions from TMEV-infected resistant B6 mice, at 8 days
p.i., with anti-TGF-b antibody was negative, and TGF-b
protein was not found in TMEV-infected B6 mice (data
not shown).
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352 CHANG ET AL.IL-4. In both strains of mice IL-4 transcripts were
FIG. 2. Anti-inflammatory cytokine transcript levels (TGF-b, IL-4, IL-5,
ate chronic demyelinating disease. Cytokine transcript levels were qu
ifferences in cytokine transcript levels between the SJL and the B6
etermined as described under Materials and Methods.xpressed at low levels in the brain (Fig. 2C) and spinal
ord (Fig. 2D) during early acute disease. These levelswere significantly increased (two- to threefold) during
-10) of TMEV-infected SJL and B6 mice during early acute disease and
d as described under Materials and Methods. Statistically significant
are marked by an asterisk, are described under Results, and wereand IL
antitatelate chronic demyelinating disease in the spinal cord of
TMEV-infected SJL mice, at 39 days p.i. (P , 0.031,
pl
t brain
353CYTOKINES IN TMEV INFECTIONKruskal–Wallis test; P , 0.044, Wilcoxon) and at 60 days
.i. (P , 0.013, Kruskal–Wallis test; P , 0.019; Wil-
coxon two-sample test). In contrast, IL-4 transcript levels
were expressed at low levels in the CNS of B6 mice
throughout the disease.
IL-5. IL-5 transcript levels were significantly higher in
the brain (Fig. 2E) of TMEV-infected SJL mice during early
acute disease and late chronic demyelinating disease, at
14 days p.i. (P , 0.014, Kruskal–Wallis test; P , 0.02;
Wilcoxon two-sample test), at 28 days p.i. (P , 0.009,
Kruskal–Wallis test; P , 0.012; Wilcoxon two-sample
test), at 39 days p.i. (P , 0.008, Kruskal–Wallis test; P ,
0.011; Wilcoxon two-sample test), and at 60 days p.i.
(P , 0.012, Kruskal–Wallis, P , 0.017; Wilcoxon two-
sample test) (Fig. 2E). However, at 14 days p.i. higher
levels of IL-5 transcripts were found in the spinal cord of
TMEV-infected B6 than in that of SJL mice (P , 0.014,
Kruskal–Wallis test; P , 0.02; Wilcoxon two-sample test)
(Fig. 2F). During late demyelinating disease, at 60 days
p.i., higher levels of IL-5 transcripts were present in the
CNS of SJL mice only (P , 0.012, Kruskal–Wallis test;
P , 0.017; Wilcoxon two-sample test). IL-5 transcript
levels in B6 mice were negligible at 60 days p.i.
FIG. 3. Immunohistochemical staining of frozen sections of brain tiss
polyclonal antibody. Frozen sections of brain tissue from TMEV-infec
immunohistochemistry using a pan-specific rabbit anti-TGF-b polyclona
-b2, and -b3). (A) Strong immunostaining of TGF-b protein was ev
eptomeninges of the medial temporal lobe SJL mice (3400). (Inset) H
immunoreactive mononuclear inflammatory cells among leptomening
lymphocytes and/or monocytes. (B) Immunostaining of adjacent cryosta
control antibody instead of primary antibody, was negative.IL-10. The profile of the IL-10 transcript levels was
similar to that of IL-5. IL-10 transcript levels were signif-icantly higher in the brain (Fig. 2G) of TMEV-infected SJL
mice during early acute disease and late chronic demy-
elinating disease at 14 days p.i. (P , 0.014, Kruskal–
Wallis test; P , 0.02; Wilcoxon two-sample test), at 39
days p.i. (P , 0.009, Kruskal–Wallis test; P , 0.012;
Wilcoxon two-sample test) and at 60 days p.i. (P ,
0.014, Kruskal–Wallis test, P , 0.02, Wilcoxon two-
sample test). However, at 14 days p.i. higher levels of
IL-10 transcripts were found in the spinal cord (Fig. 2H) of
TMEV-infected B6 mice than in the spinal cord of TMEV-
infected SJL mice (P , 0.05, Kruskal–Wallis test; P ,
0.066, Wilcoxon two-sample test). During late chronic
demyelinating disease significantly higher levels of IL-10
transcripts were present in the spinal cord of SJL mice at
39 days p.i. (P , 0.014, Kruskal–Wallis test; P , 0.02;
Wilcoxon two-sample test) and at 60 days p.i. (P ,
0.014, Kruskal–Wallis test, P , 0.02, Wilcoxon two-
sample test).
A bimodal distribution was observed with IL-5, IL-10,
and TGF-b1 transcripts in the brain and IL-10 and TGF-b1
transcripts in the spinal cord of TMEV-infected SJL mice
with one peak during early acute disease (8 days p.i.)
and a second peak at the onset of the demyelinating
TMEV-infected SJL mice at 8 days p.i. with a pan-specific anti-TGF-b
(sensitive) and B6 (resistant) mice, at 8 days p.i., were stained by
dy. This polyclonal antibody recognizes three TGF-b species (TGF-b1,
in mononuclear inflammatory cell infiltrates, primarily found in the
magnification from the same field depicting subpopulations of TGF-b
filtrates. These cells are morphologically compatible with activated
sections from TMEV-infected susceptible SJL mice, at 8 days p.i., withue from
ted SJL
l antibo
ident
igher
eal inphase of the disease (25–33 days p.i.) (Fig. 2), in a
manner similar to that observed with IL-1, IL-6, IL-12 p40,
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354 CHANG ET AL.and TNF-a transcripts in TMEV-infected SJL mice (Fig. 1).
hese bimodal distributions were not observed in TMEV-
nfected B6 mice.
DISCUSSION
We examined the expression of cytokine transcripts in
he CNS of TMEV-infected susceptible and resistant
ice with early acute and late chronic demyelinating
isease. A strong proinflammatory (Th1) cytokine re-
ponse was found in the CNS of these mice during early
cute disease. High levels of IFN-g, IL-2, IL-1, IL-6,
NF-a, and IL-12 p40 transcripts and low levels of IL-10
and IL-4 transcripts were found. During late chronic
demyelinating disease high levels of certain proinflam-
matory cytokine transcripts were present in the spinal
cord of TMEV-infected SJL mice. High levels of anti-
inflammatory TGF-b, IL-4, IL-5, and IL-10 cytokine tran-
scripts were found in the spinal cord of TMEV-infected
SJL mice with chronic demyelinating disease and may be
responsible for downregulating the proinflammatory cy-
tokine response. Many cytokine profiles followed a bi-
phasic/bimodal profile, with high levels of transcripts
appearing during early acute disease, decreased levels
on days 21 to 25 (corresponding to the end of early acute
disease and the disappearance of inflammatory infil-
trates from the brain), and then increased levels again in
the CNS of SJL mice only. As expected, the CNS of
TMEV-infected B6 mice was devoid of cytokine tran-
scripts at late times p.i. We examined cytokine transcript
levels in B6 mice at late times p.i. because it has been
reported that in rat, recovery from EAE and resistance to
relapsing disease are associated with high-level expres-
sion in the CNS of certain cytokines, and in particular,
IL-10 (Kennedy et al., 1992; Rott et al., 1994; Chen et al.,
998). Therefore, it was important to determine whether
ecovery after early acute disease of TMEV-infected B6
ice was associated with expression of IL-10 and/or
ther cytokines, produced by cells of the CNS paren-
hyma. Such an association was not observed.
We and other investigators (Wilcox and Derynck, 1988;
odmer et al., 1988; Pelton et al., 1990; Wahl et al., 1991)
ave found that normal adult mouse brain does not
xpress TGF-b transcript or protein or does so at ex-
tremely low levels. In addition, we did not detect TGF-b
protein in the leptomeninges, choroid plexus, or other
parts of the CNS of mock-infected SJL mice or TMEV-
infected B6 mice. In contrast, Unsicker et al. (1991) re-
ported that TGF-b1 protein is constitutively found in the
eptomeninges and choroid plexus of rat brain. This dif-
erence could be attributed to different species (rat vs
ouse) or to the use of anti-TGF-b antibodies raised
gainst different TGF-b peptides (Unsicker et al. (1991) vs
this study). In contrast, Theil et al. (2000) reported low-
level expression of TGF-b transcripts in normal adult
ouse brain.The proinflammatory cytokine response during early
cute disease may be essential to help clear viral infec-
ions, and it has been reported in CNS infections by other
iruses, including Borna disease virus (Hatalski et al.,
998), herpes simplex virus (Geiger, 1997), Semliki Forest
irus (Donnelly et al., 1997), and vesicular stomatitis virus
Oxenious et al., 1999). Proinflammatory cytokines during
arly acute disease are produced both by the infiltrating
nflammatory cells (primarily T cells and monocyte/mac-
ophages) and by intrinsic brain cells, such as microglia
nd astrocytes (Aloisi et al., 1992; Giulien et al., 1986;
ubio and Sierra, 1993; Sebire et al., 1993; Sierra and
ubio, 1993). The role of cytokines in enhancing, propa-
ating, and regulating antiviral immune responses is
ritical. The outcome of TMEV infection is likely to be
ffected by cytokines produced in the CNS. These cyto-
ines contribute to the recruitment and activation of in-
lammatory cells by enhancing the expression of adhe-
ion and MHC Class I and II molecules on endothelial
ells, microglia, and astrocytes and to the induction of
he differentiation of precursor to effector CTL (reviewed
y Martiney et al., 1998; Perry et al., 1995). At least three
f these proinflammatory cytokines, IFN-g (Melkova and
steban, 1994), IL-6 (formerly IFN-b2) (Weissenbach et al.,
1980), and TNF-a (Wong and Goeddel, 1986), have direct
ntiviral activity and they are able to inhibit viral replica-
ion. Along these lines, treatment of TMEV-infected SJL
ice with rIL-6 (Rodriguez et al., 1994) or rTNF-a (Paya et
l., 1990) substantially reduced the inflammatory re-
ponse, the viral titers, and the demyelinating disease.
TMEV induces in susceptible strains of mice biphasic
isease consisting of early acute encephalitic disease,
ollowed by late chronic demyelinating disease. Suscep-
ible mouse strains failed to clear the virus and this
esults in viral persistence and demyelination. In con-
rast, resistant strains of mice develop early acute dis-
ase and completely clear the virus. It is not known why
he virus is not eliminated in the CNS of susceptible SJL
ice. CTL are critical for clearing viral infections. TMEV-
nfected B6 mice developed a strong TMEV-specific CTL
esponse as early as 3 days p.i. In contrast, in SJL mice,
MEV-specific CTL responses appeared much later and
emained very low throughout the disease, to 180 days
.i. (Dethlefs et al., 1997; Lin et al., 1995; Lindsley et al.,
1991), although CD81 infiltrating T cells of unknown func-
ion have been reported in the CNS of TMEV-infected SJL
ice at 11 days p.i. (Lindsley and Rodriguez, 1989).
imiting dilution analysis revealed that the TMEV-spe-
ific CTL precursor frequency in B6 mice is 1 in 7200 at
0-days p.i., whereas in SJL mice this frequency was
uch lower, 1 in 125,000 precursors (Dethlefs et al.,
997). Several lines of evidence demonstrate that CD81
CTL are very important in clearing the virus during early
acute disease: (a) adoptive transfer of CD81 T cells from
TMEV-primed BALB/cByJ resistant mice to TMEV-in-
fected BALB/cAnNcr susceptible mice could protect
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355CYTOKINES IN TMEV INFECTIONthese mice against demyelinating disease, if the transfer
is carried out sufficiently early in the disease to allow for
clearance of the virus (Nicholson et al., 1996); (b) resis-
tance to TMEV-induced demyelinating disease in B6
mice is determined by the H-2Db locus (Azoulay et al.,
994); and (c) TMEV-infected DBA/2 mice are protected
rom TMEV-induced demyelinating disease by in vivo
reatment with rIL-2 (Larsson-Sciard et al., 1997).
We have identified for the first time major differences
n the levels of cytokine transcripts expressed in the CNS
etween SJL (susceptible) and B6 (resistant) strains of
ice, as follows:
1. Statistically significant differences in the levels of
GF-b1 and TNF-a transcripts were observed between
SJL and B6 mice during early acute and late chronic
demyelinating disease. Very low levels of TGF-b1 and
TNF-a transcripts were observed in the brains of B6 mice
with early acute disease at 8 days p.i. In contrast, TGF-b1
and TNF-a transcripts were increased by 9- to 10-fold in
the brain and spinal cord of TMEV-infected SJL mice with
early acute disease. Immunohistochemical staining re-
vealed the presence of TGF-b protein in the CNS of SJL
ice with early acute disease, but not in the CNS of B6
ice. Sato et al. (1997) and Begolka et al. (1998) did not
nvestigate the expression of TGF-b in the CNS of TMEV-
infected mice. Additionally, in contrast to our findings
Sato et al. (1997) (a) reported higher levels (although not
statistically significant) of TNF-a transcripts in the brain
f B6 mice than in that of SJL mice at 8 days p.i. and (b)
id not find differences in TNF-a transcripts in the spinal
ord of B6 and SJL mice at 8 days p.i. Begolka et al.
1998) did not find any TNF-a transcripts in the spinal
ord of TMEV-infected (BeAn strain) SJL mice, during the
irst 26 days p.i. Theil et al. (2000) reported the expres-
ion of TGF-b transcripts in normal adult mouse brain
nd did not pursue further the analysis of the expression
f TGF-b in TMEV-infected mice. The reasons for these
differences are not known.
TGF-b is an immunoregulatory protein with extensive
immunosuppressive properties (reviewed by Roberts and
Sporn, 1990). TGF-b inhibits proliferation of T cells
(Schluesener and Lider, 1989), generation of CTL and LAK
effector cells (Fontana et al., 1989; Kuppner et al., 1988);
expression of MHC class II (Schluesener and Lider, 1989),
activation of microphages and of glia cells by suppressing
the production of reactive oxygen intermediates (Suzumura
et al., 1993), and cytokine production by microglia and
monocyte/macrophages (Schluesener and Lider, 1989).
The expression of TGF-b in the CNS of TMEV-infected SJL
ice, but not B6 mice, suggests that TGF-b may be respon-
sible, at least in part, for the delayed appearance and the
low cytotoxic activity throughout the disease of TMEV-spe-
cific CTL in the CNS of SJL mice. Clearance of the virus
requires substantial and timely CTL responses. Absent or
very low levels of antiviral CTL activity may have profoundconsequences, resulting in the failure to clear the virus,
permitting the establishment of viral persistence and end-
ing with the development of demyelinating disease. SJL
mice do not appear to have an intrinsic defect in generating
strong antiviral CTL responses. Semliki Forest virus (SFV)-
infected SJL mice (another model for virally induced en-
cephalitis and demyelinating disease) are able to clear SFV,
had lower viral titers in the brain, and developed less
severe disease than B6 mice (Mokhtarian et al., 1996; Don-
nelly et al., 1997).
TNF-a is a strong inducer of several inflammatory cyto-
ines, appears to be directly cytotoxic against various cell
ypes, and enhances the expression of MHC class I and
dhesion molecules on endothelial cells (reviewed by
racey and Cerami, 1994; Vassalli, 1992). Furthermore,
NF-a may be responsible for direct damage of myelin and
ligodendrocytes (Selmaj and Raine, 1988). A correlation
as been demonstrated between the extent of demyelinat-
ng disease and the levels of TNF-a in experimental allergic
encephalomyelitis (Dal Canto et al., 1999; Ruddle et al.,
1990; Selmaj et al., 1991), TMEV-infected mice (Inoue et al.,
1996), and multiple sclerosis (Rieckmann et al., 1995; Shar-
ief and Hentges, 1991; Selmaj and Raine, 1988). However,
other studies have shown that TNF-a exhibits both proin-
lammatory and anti-inflammatory properties and may play
regulatory role in maintaining homeostatis. TNF-a pro-
tects mice from developing certain autoimmune disorders,
such as diabetes (Jacob et al., 1992) and lupus erythema-
tosus (Jacob et al., 1996). Additionally, TNF-a knockout mice
immunized with myelin oligodendrocyte glycoprotein de-
velop much more severe inflammatory and demyelinating
disease than their normal TNF11/11 littermates (Liu et al.,
1998).
2. High levels of IL-2 transcripts and IL-2-protein-pro-
ducing cells appeared in the spinal cord of TMEV-in-
fected SJL mice at 25–39 days p.i. and then declined.
These transiently increased IL-2-expressing cells were
observed only in SJL mice, appeared at the onset of
demyelinating disease, and may be expanding clones of
T cells that may be responsible, at least in part, for
demyelinating disease. This explains their low numbers.
The antigenic specificity of these T cells is not known.
This transient increase in IL-2-expressing cells in the
CNS of TMEV-infected SJL mice at the onset of demyeli-
nating disease has been observed for the first time here.
It has not been reported by Sato et al. (1997), who also
used the DA strain of TMEV, perhaps because they
studied only four time points during the course of the
disease. Begolka et al. (1998) employed the BeAn strain
of TMEV, which caused considerably different disease
than the DA strain. IL-2 transcript expression was not
examined by Begolka et al. (1998). IL-2 is the predomi-
nant T-cell growth factor; it is produced by activated T
cells (autocrine system) and promotes the activation,
proliferation, and cell division of T and B cells and of
monocytes.
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356 CHANG ET AL.3. Substantial levels of anti-inflammatory cytokine
transcripts (IL-4, IL-5, IL-10, and TGF-b) were observed in
the CNS of TMEV-infected SJL mice with late chronic
demyelinating disease. IL-4 is a growth factor of T and B
lymphocytes and cells of the monocyte/macrophage lin-
eage, although it is not as potent as IL-2, and it also
induces class I and II MHC antigen expression (re-
viewed by Paul, 1991). IL-4 inhibits the generation of CTL
by IL-2 (Sharma et al., 1996; Tang and Graham, 1994;
illacres and Bergmann, 1999). IL-4 downregulates Th1-
nduced inflammation and inhibits (along with IL-10 and
GF-b1) the activation of monocyte/macrophages and
the production by these cells of proinflammatory cyto-
kines, such as IL-1, IL-12, IL-6, and TNF-a (Abramson and
Gallin, 1990; Chao et al., 1993; Wong et al., 1992; Hart et
al., 1989). The presence of high levels of IL-4 during late
chronic demyelinating disease in SJL mice may contrib-
ute to inhibition of the proinflammatory response, deac-
tivation of monocyte/macrophages, and inhibition of the
generation of antiviral CTL. Thus, IL-4 may be responsi-
ble, at least in part, for perpetuating viral persistence
during late chronic demyelinating disease. Our results
are in agreement with those of Sato et al. (1997), who
also found high levels of IL-4 transcripts in the spinal
cord of TMEV-infected SJL mice with late demyelinating
disease. However, Sato et al. (1997) also reported very
low levels of IL-4 transcripts in the spinal cord of TMEV
susceptible DBA/2J mice with chronic demyelinating dis-
ease, suggesting that IL-4 expression may not be re-
quired for the development of demyelinating disease.
In conclusion, significant differences were found in the
levels of cytokine transcripts expressed in the CNS of
TMEV-infected susceptible (SJL) and resistant (B6) mice
during early acute and late chronic demyelinating dis-
ease. Certain of these differences, such as those in
TGF-b and TNF-a in the brain of SJL mice vs B6 mice at
8 days p.i., may be responsible for the inability of SJL
mice to clear the virus and for the severity of the demy-
elinating disease in the spinal cord of SJL mice.
MATERIALS AND METHODS
Animals. Five- to 6-week-old SJL and C57BL/6 female
mice (The Jackson Laboratory, Bar Harbor, ME) were
injected ic with approximately 1.5 3 105 PFU of TMEV-DA
strain (Oleszak et al., 1988, 1997). Three to five infected
animals were sacrificed and perfused with phosphate-
buffered saline (PBS) at 8, 14, 21, 25, 28, 33, 39, and 60
days p.i. and the brains and spinal cords from these mice
were analyzed individually for cytokine transcript expres-
sion. Brains and spinal cords from uninfected and mock-
infected (as described by Oleszak et al., 1997) SJL mice
were also analyzed for cytokine transcript expression.
RNA extraction. Individual tissue was homogenized in
a 2-ml tissue grinder in 1 ml of denaturing solution
(guanidium isothiocyanate, Stratagene RNA Isolation Kit,Stratagene, La Jolla, CA). RNA was purified from the CNS
tissue following the recommendations of the manufac-
turers with the exception that the method was scaled
down to 1/10 of that recommended. RNA concentration
and purity were determined using OD260/280 (UV/VIS Spec-
trometer Lamda 2, Perkin–Elmer, Norwalk, CT).
Synthesis of cDNA. Ten micrograms of RNA was used
in a cDNA synthesis reaction using 500 units of Super-
script II RNase H-negative Reverse Transcriptase (Gibco
BRL, Gaithersburg, MD), following the manufacturer’s
protocol. In brief, RNA was incubated with 2.5 mg oli-
o(dT)15 primer (Promega, Madison, WI) at 70°C for 10
min. RNA was transferred to ice, the Superscript II cock-
tail was added, and cDNA synthesis was allowed to
occur at 42°C for 1 h in the presence of approximately 10
U RNasin (Promega).
Cytokine-specific PCR. One microliter of cDNA was
used in a 100-ml PCR using Taq polymerase (Promega) at
units/reaction. Two microliters of 10 mM dNTPs (Am-
rsham Pharmacia Biotech, Piscataway, NJ) cocktail was
sed for each reaction. Cytokine-specific PCR was per-
ormed for IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IFN-g,
NF-a, and TGF-b1 using cytokine-specific primers, as
ollows: IL-1: sense, ATGGCAACTGTTCCTGAACT-
AACT; antisense, CAGGACAGGTATAGATTCTTTCCTTT.
L-2: sense, TTCAAGCTCCACTTCAAGCTCTACAGCGGA;
ntisense, GACAGAAGGCTATCCATCTCCTCAGAAGCC.
L-5: sense, GTGGGCCGCTCTAGGCACCAA; antisense,
TCTTTGATGTCACGCACGATTTC. IL-10: sense, ATG-
AGGACTTTAAGGGTTACTTGGGTT; antisense, ATTCG-
AGAGAGGTACAAACGAGGTTT. b-actin: sense, GTGGG-
CCGCTCTAGGCACCAA; antisense, CTCTTTGATGTCAC-
GCACGATTTC. (All these oligonucleotide sequences
were provided from mouse RT-PCR Amplimer Sets (Clon-
tech).) IL-4: sense, TCTTTCTCGAATGTACCAGG; anti-
sense, CATGGTGGCTCAGTACTACG. IL-6: sense, TGCT-
GGTGACAACCACGGCC; antisense, GTACTCCAGAA-
GACCAGAGG. IFN-g: sense, AGCTCTGAGACAATGA-
CGC; antisense, GGACAATCTCTTCCCCAGCC. TNF-a:
sense, TTGACCTCAGCGCTGAGTTG; antisense, CCTG-
TAGCCCACGTCGTAGC. TGF-b1: sense, GAAGCCATC-
CGTGGCCAGAT; antisense, GACGTCAAAAGACAGC-
CACT (Wesselingh et al., 1994). IL-12: sense, ATGGCCAT-
GTGGGAGCCTGGAGAAA; antisense, GTGGAGCAG-
CAGATGTGAGTGGCT (Reiner et al., 1993).
b-actin-specific PCR was performed using a mouse
b-actin Control Amplimer Set (Clontech, Palo Alto, CA) on
a Model 480 DNA thermal cycler (Perkin–Elmer, Norwalk,
CT).
PCR conditions were as follows: for b-actin, IL-1, IL-2,
IL-5, IL-10, and IL-12, templates were denatured at 94°C
for 45 s, annealed at 60°C for 45 s, and extension
occurred at 72°C for 2 min. For IL-4, IFN-g, TNF-a, and
TGF-b1, denaturing occurred at 95°C for 45 s, annealing
at 60°C for 45 s, and extension at 72°C for 30 s. Follow-
ing 40 cycles of reaction, all samples were allowed to
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357CYTOKINES IN TMEV INFECTIONextend at 72°C for 10 min. Internal positive controls for
b-actin, IL-1, IL-2, IL-5, IL-10 PCR were provided in the
RT-PCR Amplimer sets (Clontech). p2a-e3 plasmid en-
coding IL-4 cDNA (ATCC, Rockville, MD) was used as an
internal control for IL-4-specific PCR and pms-10 plasmid
encoding IFN-g cDNA (ATCC) was used as an internal
positive control for IFN-g-specific PCR. As an internal
ositive control for IL-6-, IL-12-, TNF-a-, and TGF-b1-
specific PCRs, cDNAs derived from mouse splenocytes
that were activated with 10 mg/ml LPS (Sigma–Aldrich,
t. Louis, MO) for 48 h were used. Twenty microliters of
ach of the PCR samples was run on a 1% agarose gel
ith ethidium bromide and then used for Southern blot
ybridization.
Blotting. PCR samples were electrophoresed on 1%
agarose gel (Medium EEO, Fisher Scientific, Pittsburgh,
PA) with ethidium bromide. The gel was placed in dena-
turing solution (0.5 N NaOH, Fisher Scientific) for 30 min
prior to transfer. DNA was vacuum-transferred to nylon
membranes (Biotrans, ICN Pharmaceuticals, Costa
Mesa, CA), in the presence of 103 SSC, for 90 min at 15
in. Hg (Model 785 Vacuum Blotter, Bio-Rad, Hercules,
CA). Nylon membranes were transferred to 23 SSC for 5
in and then they were UV cross-linked (UV Stratalinker
400, Stratagene).
Southern blot hybridization. The following cytokine-
pecific internal hybridization probes were used: IL-1,
GCTTTCAGCTCATATGGGTCCGACAGCAC; IL-2, TGA-
CATCCTGGGGAGTTTCAGGTTCCTGT; IL-5, TGCAT-
GCTGGTGATTTTTATGAGTAGGGA; IL-10, GCCTTGTA-
ACACCTTGGTCTTGGAGCTTA (all these oligonucleo-
ide sequences were provided from mouse RT-PCR
mplimer sets, Clontech); IL-4, GACCTCGTTCAAAATGC-
GATGATCTCTCT; IL-6, GCCATTGCACAACTCTTTTCT-
ATTTCCAC; IFN-g, GATTTTCATGTCACCATCCTTTTGC-
CAG; TNF-a, CTGGAAGACTCCTCCCAGGTATATGGGTTC;
GF-b1, TCTCTGCAAGCGCAGCTCTGCACGGGACAG-
CAA (all described by Wesselingh et al., 1994);
IL-12, ATGTCATCTTCTTCAGGCGTGTCACAGGTGAGGTT
(Reiner et al., 1993).
Probes were end-labeled with 200 pmol [g-32P]ATP
(300 mCi/ml) using T4 kinase (Promega). PCR products
were transferred to nylon membranes (Biotrans, ICN,
Costa Mesa, CA) by vacuum blotting (Bio-Rad), as de-
scribed in the previous paragraph, and were hybridized
with cytokine-specific probes. The blots were incubated
with prehybridization buffer (63 SSC, 53 Denhardt’s
solution, containing 100 mg/ml salmon sperm DNA;
Gibco BRL) at 65°C in a hybridization oven (Micro 4,
Hybaid, Franklin, MA) for 3 h. Hybridization was per-
formed at 42°C for 3 h in 63 SSC, 53 Denhardt’s solu-
tion containing 100 mg/ml salmon sperm DNA (Gibco
BRL), and 20 3 10212 mol 32P-end-labeled probe. Subse-
uently, the blots were washed twice at room tempera-
ure (15 min each) and once at 65°C (for 45 min) to wash
way unbound probes. The blots were then transferredo an autoradiography cassette and the films were ex-
osed for 1 h at 270°C.
Densitometric analysis. The developed films were
canned (Scanjet II, Hewlett Packard), and the densities
ere measured using the software SigmaGel (Statistical
olutions Ltd., Saugus, MA). Quantitative analysis was
erformed by normalizing the samples to the internal
CR controls described above (see Cytokine-Specific
CR), which also served as positive controls for each
ytokine analyzed. The levels of each cytokine in each
ample were then graphed with respect to b-actin levels
for the corresponding samples.
Immunohistochemistry. TMEV-infected mouse brains
were embedded in O.C.T. (Miles Inc., Elkhart, IN) and
cryosectioned at 5 mm. The sections were fixed in cold
cetone (220°C) for 10 min and then air-dried. Prior to
eing stained, the sections were rehydrated in PBS con-
aining 0.5% saponin (PBS–saponin) (Sigma, St. Louis,
O) for 10 min. The sections were then incubated in
BS–saponin with normal goat serum (Vector Laborato-
ies, Burlingame, CA) for 30 min at room temperature.
fter the removal of the blocking goat serum, the slides
ere incubated with a pan-specific rabbit TGF-b anti-
ody (R&D Systems, Minneapolis, MN) at 2 mg/ml for 2 h.
his polyclonal antibody recognizes three TGF-b species
(TGF-b1, -b2, and -b3) and has been reported to recog-
nize the active form of TGF-b1 (Su et al., 1991). After the
slides were washed three times for 10 min each with
PBS–saponin, biotinylated goat anti-rabbit antibody (ABC
Elite, Vector Laboratories) was added and the slides
were incubated for 30 min. After being washed three
times for 10 min each with PBS–saponin, the slides were
incubated in avidin–horseradish peroxidase complex so-
lution following the manufacturer’s protocol (ABC Elite,
Vector Laboratories). DAB (Vector Laboratories) was
used as a chromogen and tissue sections were counter-
stained with Meyer’s hematoxilin (Fisher Scientific).
Isolation of murine T cells from the CNS. Mice were
anaethesized with isofluorane (Abbott Laboratories, Chi-
cago, IL) and then were perfused with PBS. Brains and
spinal cords were harvested and meshed through a
100-mesh tissue sieve (E-C Apparatus Corp., St. Peters-
burg, FL) in RPMI 1640 (Mediatech, Herndon, VA) sup-
plemented with 5% FCS (Gibco BRL) and penicillin/strep-
tomycin (Mediatech). Cells were transferred to 50-ml
tubes and centrifuged at 300g for 10 min. Cells from two
brains were resuspended in 4 ml of 68% Percoll (Sigma)
in PBS, and cells from two spinal cords were resus-
pended in 4 ml of 70% Percoll in PBS and transferred to
15-ml tubes. The cell suspensions were then overlaid
gently with 30% Percoll in PBS and centrifuged at 400g
for 25 min at room temperature. The cells were collected
from the interphase and washed twice with PBS.
Intracellular staining for IL-2. Cells isolated from the
CNS of SJL or B6 mice were cultured for 4 h with RPMI
1640 supplemented with 5% FCS and 10 mg/ml of Brefel-
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358 CHANG ET AL.din A (PharMingen, San Diego, CA). Cells were washed
with PBS containing 0.1% gelatin (Sigma) and 1% BSA
and were incubated with 0.5 mg/50 ml of FITC-labeled
anti-mouse CD3 MAb or anti-mouse CD4 MAb or anti-
mouse CD8 MAb (Pharmingen) for 30 min on ice. The
cells were washed twice with PBS containing 1% gelatin
and then fixed with 500 ml of 4% paraformaldehyde for 10
in on ice. The cells were washed twice with PBS
ontaining 1% gelatin and were resuspended in 200 ml
BS containing 0.1% saponin and 2% gelatin for 15 min at
oom temperature. The cells were washed twice with
BS containing 0.1% saponin. After being washed, the
ells were resuspended in 100 ml of PBS containing 0.1%
aponin and 0.5 mg/100 ml of PE-labeled anti-mouse IL-2
(Pharmingen) and were incubated for 30 min on ice. The
cells were washed once with PBS containing 0.1% sapo-
nin and resuspended in 100 ml of PBS containing 0.1%
aponin for 30 min at room temperature in order to allow
xcess antibody to leak out. The cells were washed with
BS containing 0.1% saponin and then were fixed in 500
ml of 4% paraformaldehyde. FACS analysis was per-
formed using an EPICS XL Flow Cytometer (Coulter
Corp., Hialeah, FL).
Mouse intracellular cytokine-1 (MiCK-1) cells were
used as positive control and were purchased from
PharMingen. These cells are polyclonally activated
mouse spleen lymphocytes, in the presence of a protein
transport inhibitor. After stimulation the cells were incu-
bated with a rat antibody specific for CD16/CD32 (Fcg
II/III receptor) to reduce Fc receptor-dependent immuno-
fluorescence straining. Subsequently, the cells were
fixed and stored frozen in 10% dimethylsulfoxide and 90%
fetal bovine serum at 280°C. Following the specifica-
tions of the manufacturer, the MiCK-1 cells were thawed,
washed, stained with anti-CD3 MAb, anti-CD4 MAb, or
anti-CD8 MAb, incubated for 10 min in permeabilization
buffer, washed, and stained with PE conjugated rat anti-
mouse IL-2 antibody.
Statistical analysis. Statistical analysis was carried out
y the Wilcoxon two-sample test (normal approximation
ith continuity correction of 0.5) and the Kruskal–Wallis
est (x2 approximation).
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